The Endometriosis market report also offers comprehensive insights into the Endometriosis market size, share, Endometriosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Endometriosis market size growth forward.
Some of the key highlights from the Endometriosis Market Insights Report:
Endometriosis is a condition in which patches of endometrial tissue, which normally lines the inside of the uterus, grow outside the uterus—on the fallopian tubes, ovaries, and sometimes even the lungs. During the menstrual cycle, the endometrium thickens and increases its blood supply in preparation for the release of an egg. If the egg is not fertilized, the body sheds the endometrial lining. However, when endometrial tissue is located outside the uterus, it still undergoes this cycle, leading to pain, swelling, and bleeding in the affected areas.
Endometriosis is categorized into four stages based on the extent of endometrial implants outside the uterus: Stage 1 (minimal), Stage 2 (mild), Stage 3 (moderate), and Stage 4 (severe). Stage 4 represents the most advanced form, characterized by deep implants and extensive adhesions.
Several factors can increase the risk of developing endometriosis, including never having given birth, early onset of menstruation (menarche), late menopause, short menstrual cycles, family history (such as a mother, aunt, or sister with the condition), and other reproductive tract disorders.
A significant challenge in diagnosing endometriosis is the delay in diagnosis, which typically averages 6 to 10 years. This delay is often due to challenges in referral from primary care to specialists and the overlapping symptoms with other conditions.
In 2023, the diagnosed prevalent cases of endometriosis across the 7MM (the seven major pharmaceutical markets) were approximately 10.77 million. Among these cases, moderate endometriosis accounted for the largest share (~40%), followed by severe and mild cases, respectively.
The total market size for endometriosis in the 7MM was valued at USD 2.3 billion in 2023, with expectations for significant growth over the forecast period, driven by the introduction of new therapies.
Despite advancements in treatment, the current pharmacological landscape for endometriosis has several limitations. Hormonal therapies can interfere with fertility, making them unsuitable for all patients. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used off-label for pain relief, but long-term use may lead to kidney damage. Additionally, opioids, while effective for pain, carry a high risk of addiction.
To address these limitations, a number of new therapies are under development, including OG-6219 (Organon), linzagolix (ObsEva SA), HMI-115 (Hope Medicine), and VML-0501 (Viramal), among others. Among these emerging therapies, OG-6219 is expected to capture the largest market share by 2034.
The growth of the endometriosis market is expected to be driven primarily by the introduction of novel therapies with improved clinical profiles, a surge in research and development, and a deeper understanding of the disease. The market is also anticipated to expand due to the increasing use of existing treatments, such as NSAIDs and opioids, alongside the anticipated approval of promising pipeline candidates like OG-6219 and elagolix + estradiol + norethindrone.
In 2023, the total market size for endometriosis across the 7MM was approximately USD 2.3 billion. Prescription analgesics, including NSAIDs and opioids, currently hold the largest market share and are expected to continue dominating the market throughout the forecast period.
The United States accounted for the largest share of the endometriosis market in the 7MM, with an estimated market size of around USD 1.4 billion in 2023. Within the EU4 and UK region, the UK had the highest market share at approximately 20%, while Spain represented the smallest share.
Market growth is primarily driven by the anticipated introduction of promising pipeline therapies such as OG-6219 and elagolix + estradiol + norethindrone during the forecast period from 2024 to 2034.
Overall, the market size is expected to grow significantly during the period from 2020 to 2034, as new, more effective treatments emerge to address the unmet needs of patients with endometriosis.
Strategise your business goals by understanding market dynamics @ Endometriosis Market Landscape
Endometriosis Overview
Endometriosis is a condition in which endometrial tissue, which normally lines the inside of the uterus, grows outside the uterus. This ectopic tissue responds to hormonal fluctuations during the menstrual cycle, leading to recurring bleeding and the formation of fibrous tissue in areas where it shouldn’t be. The condition primarily affects adolescents and women of reproductive age and is often associated with chronic pelvic pain and infertility. The most common sites for endometriosis include the ovaries, pelvic peritoneum (the membrane lining the pelvic cavity), uterosacral ligaments, and torus uterinus. However, it can also occur in less typical areas, such as the cervix, round ligaments, ureter, and nerves. In rare cases, endometrial implants can be found outside the pelvic region, including the upper abdomen, subphrenic fold, or abdominal wall.
Diagnosing endometriosis is often challenging, with an average delay of 4 to 11 years from the onset of symptoms. This delay is primarily due to the lack of a definitive test or biomarker for the condition, as well as the overlap of symptoms with other gastrointestinal or gynecological disorders. Symptoms like pain during menstruation are often dismissed as normal, making it difficult to pinpoint the underlying issue. To diagnose endometriosis accurately, healthcare providers typically take a thorough medical history and conduct a gynecological physical examination. The gold standard for diagnosis is laparoscopy, a surgical procedure in which the abdominal cavity is examined and a tissue sample is collected for histological analysis. However, ultrasound and MRI can also be useful in detecting ovarian endometriomas (cysts) and deep nodular forms of the disease.
The management of endometriosis requires a comprehensive, multidisciplinary approach. Treatment typically includes a combination of surgical intervention, hormonal therapy, pain management, and pelvic therapy. Surgery is often used both for diagnostic purposes and to remove endometrial lesions. Hormonal therapies aim to suppress the disease and prevent its recurrence or progression, while pain management strategies, often provided through specialized pain centers, help alleviate discomfort. Although both surgical and medical treatments can effectively manage the symptoms of endometriosis, recurrence of the disease is common.
Medical treatment options vary depending on the severity of symptoms, side effects, cost considerations, and patient preferences. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as the first-line treatment for pain relief, often in combination with low-dose combined oral contraceptive pills (COCPs) containing ethyl estradiol and progestins. If NSAIDs do not provide adequate relief within three months, other treatments, such as progestins (which can be administered orally, by injection, or via intra-uterine devices), androgens, and gonadotropin-releasing hormone agonists (GnRH), may be considered to manage moderate to severe pain associated with endometriosis.
Do you know the treatment paradigms for different countries? Download our Endometriosis Market Sample Report
Endometriosis Epidemiology Segmentation
DelveInsight’s Endometriosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Endometriosis historical patient pools and forecasted Endometriosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Endometriosis Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
Endometriosis Prevalence
Age-Specific Endometriosis Prevalence
Gender-Specific Endometriosis Prevalence
Diagnosed and Treatable Cases of Endometriosis
Visit for more @ Endometriosis Epidemiological Insights
Recent Advances in the Endometriosis Market:
FDA approves Myfembree for endometriosis pain: In August, 2022, Myovant announced the US Food and Drug Administration (FDA) has approved relugolix combination tablets (Myfembree; Myovant Sciences and Pfizer) for the treatment of moderate-to-severe endometriosis-associated pain. Previously, Myfembree was only approved for the management of uterine fibroid-related heavy menstrual bleeding in premenopausal women. “This approval is an important milestone reflecting Pfizer and Myovant’s commitment to women’s health in areas of significant unmet need,” said James Rusnak, MD, PhD, senior vice president, chief development officer, Internal Medicine and Hospital, Global Product Development at Pfizer. “We look forward to making Myfembree available to women with endometriosis and broadening their options in managing this complex disorder.”
Endometriosis Treatment Market
While there is currently no cure for endometriosis, treatments primarily focus on managing symptoms, particularly pain and infertility. These treatments include drug therapies (analgesics and hormonal treatments) and surgery. Although drug therapies are effective in alleviating pain, surgery remains the only option that has been shown to improve fertility outcomes. Current treatment guidelines for endometriosis emphasize pain management and addressing infertility. Commonly recommended treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), combined hormonal contraceptives, progestogens (or antiprogestogens), gonadotropin-releasing hormone (GnRH) agonists and antagonists, surgical removal (fulguration or excision) of endometrial lesions, and hysterectomy, with or without bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes).
Several novel therapies with innovative mechanisms of action are currently in development for endometriosis. These include LHRH receptor antagonists, gonadotropin-releasing hormone stimulants, and prolactin receptor antagonists, among others. Key players in this space, such as ObsEva SA, Myovant Sciences, Hope Medicine, and Organon, are driving the development of these new treatment options.
In conclusion, while the current treatment landscape for endometriosis still lacks a definitive solution, numerous promising therapies with novel mechanisms are on the horizon. These emerging treatments are expected to address the significant unmet need in the market, leading to substantial improvements in patient outcomes. As new therapies become available and healthcare spending continues to rise across the 7MM, the treatment landscape for endometriosis is poised for significant growth over the forecast period (2024–2034).
Endometriosis Therapy Assessment
Linzagolix: ObsEva
ObsEva is currently advancing linzagolix, a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of endometriosis-associated pain. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately dose-dependently reducing estrogen production by the ovaries. Through previously reported results from linzagolix and sophisticated pharmacological modelling, it has been established that maintaining estradiol within a specific target range provides the optimal balance between reducing symptoms while mitigating bone density loss associated with excessive estradiol suppression. In 2015, ObsEva in-licensed Linzagolix from Kissei Pharmaceutical Co., which had completed several Phase 2a clinical trials in Japan.Currently, the drug is being evaluated in Phase III clinical trial evaluation for the treatment of Endometriosis.
Relugolix: Myovant Sciences
Relugolix Combination Tablet consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the treatment of endometriosis and for the prevention of pregnancy. Phase III clinical program for endometriosis consisted of two multinational, replicate pivotal clinical studies (SPIRIT 1 and SPIRIT 2) of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis. In January 2021, Myovant Sciences and Pfizer Inc. announced that the Phase III SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss.
Endometriosis Key Companies
AbbVie
Neurocrine Biosciences
ObsEva
Kissei Pharmaceuticals
SWK
Enteris BioPharma
Bayer
Hope Medicine
Tiumbio
Organon
For more information, visit Endometriosis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Endometriosis Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Endometriosis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Endometriosis epidemiology in the 7MM
Endometriosis marketed and emerging therapies
Endometriosis companies
Endometriosis market drivers and barriers
Key Questions Answered in the Endometriosis Market Report 2034:
What was the Endometriosis market share distribution in 2020, and how would it appear in 2034?
What is the total Endometriosis market size and the market size by therapy across the 7MM for the study period (2020-32)?
What are the important findings from 7MM, and which country will have the greatest Endometriosis market size from 2020-32?
During the study period (2020-2034), at what CAGR is the Endometriosis market projected to expand at 7MM?
Table of Contents:
1 Endometriosis Market Key Comprehensive Insights
2 Endometriosis Market Report Introduction
3 Competitive Intelligence Analysis for Endometriosis
4 Endometriosis Market Analysis Overview at a Glance
5 Executive Summary of Endometriosis
6 Endometriosis Epidemiology and Market Methodology
7 Endometriosis Epidemiology and Patient Population
8 Endometriosis Patient Journey
9 Endometriosis Treatment Algorithm, Endometriosis Current Treatment, and Medical Practices
10 Key Endpoints in Endometriosis Clinical Trials
11 Endometriosis Marketed Therapies
12 Endometriosis Emerging Therapies
13 Endometriosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Endometriosis
16 Endometriosis Market Key Opinion Leaders Reviews
18 Endometriosis Market Drivers
19 Endometriosis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Endometriosis Epidemiology 2034
DelveInsight’s “Endometriosis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Endometriosis Pipeline 2023
“Endometriosis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Endometriosis market. A detailed picture of the Endometriosis pipeline landscape is provided, which includes the disease overview and Endometriosis treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
